Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active antiretroviral therapy

Clinical Therapeutics

Volumn 21, Issue 8, 1999, Pages 1313-1320

  Pradier, Christian ^a   Pesce, Alain ^a   Carrieri, Patrizia ^b   Cottalorda, Jacqueline ^c   Boyer, Patrice ^a   Senesi, Christian ^a   Fuzibet, Jean Gabriel ^a   Dellamonica, Pierre ^a   Cassuto, Jill Patrice ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Highly active antiretroviral therapy; HIV; Indinavir; Protease inhibitors; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

EID: 0032840105     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80032-0     Document Type: Article

References (24)

1. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération des Centres de Lutte contre le SIDA. AIDS. 1997;11:F101-F105.
2. Palella F Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
4. Direction des Hôpitaux-Mission SIDA-INSERM SC4. DMI-2, a System Built Around the Patient. Paris: Ministère de la Santé; 1992.
5. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA. 1997;227:1962-1969.
6. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
7. Hammer SM, Squires KE, Hugues MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell count of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
8. Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11:F113-F116.
9. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS. 1998;12:2161-2167.
10. Casado JL, Perez-Elias MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS. 1998;12:F131-F135.
11. Lederberger B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet. 1999;353:863-868.
12. Descamps D, Peytavin G, Calvez V, et al. Virologic failure, resistance and plasma drug measurements in induction maintenance therapy trial (ANRS 072, Trilège). In: Program and abstracts of the 6th Conference on Retrovirus and Opportunistic Infections; January 31-February 4, 1999; Chicago, Illinois. Abstract 493.
13. Hecht F, Grant R, Petropoulos C, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-311.
14. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454.
15. Selby JV. Case-control evaluations of treatment and program efficacy. Epidemiol Rev. 1994;16:90-101.
16. Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs. 1996;52;93-112.
17. d'Arminio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS. 1998; 12:1631-1637.
18. Clumeck N, Colebunders B, Vandercam B, et al. Randomized comparative outcomes trials of indinavir and ritonavir in protease inhibitor-naive HIV patients with CD4 below 100 cells/μl. In: Program and abstracts of the 5th Conference on Retrovirus and Opportunistic Infections; February 1-5, 1998; Chicago, Illinois. Abstract 386.
19. Katlama C, Valantin MA, Vasquez V. ALTIS Plus: Long term D4T-3TC with and without ritonavir. In: Program and abstracts of the 5th Conference on Retrovirus and Opportunistic Infections; February 1-5, 1998; Chicago, Illinois. Abstract 376.
20. Hertogs K, Mellors JW, Schel P, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates. In: Program and abstracts of the 5th Conference on Retrovirus and Opportunistic Infections; February 1-5, 1998, Chicago, Illinois. Abstract 395.
21. Dulioust A, Paulous S, Guillemot L, et al. Selection of saquinavir-resistant mutants following a switch from saquinavir. Antiviral Ther. In press.
22. Ballard C, Toerner JG, Colwell B, Mathews WC. Early CD4, viral load and quality of life response to salvage treatment with nelfinavir: The UCSD Owen Clinic nelfinavir expanded access experience. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Canada. Abstract 1-89.
23. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1 specific CD4+ T-cell responses associated with control of viremia. Science. 1997;278:1447-1450.
24. Gorochov G, Neumann AU, Kereveur A, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med. 1998;2:215-221.